Study identifier:D2080C00009
ClinicalTrials.gov identifier:NCT00892944
EudraCT identifier:2008-008343-23
CTIS identifier:N/A
An open label Positron Emission Tomography (PET) study with [11C]AZ12713580 to determine central mGluR5 receptor occupancy of AZD2516 after oral administration to healthy subjects
Healthy
Phase 1
Yes
AZD2516
All
6
Interventional
20 Years - 45 Years
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Jun 2025 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.
Location
Location
Stockholm, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD2516 | Drug: AZD2516 Fractionated single oral dose |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.